Trametinib
Sign in to save this workspacePrimary targets: MEK1, MEK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.50
Gini
0.718
CATDS
0.056
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Trametinib. Strongest target: MEK1 at 98.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | MEK1 | 98.7% | 1.3% |
| 2 | MEK2 | 93.1% | 6.9% |
| 3 | PDK2_PDHK2 | 40.0% | 60.0% |
| 4 | CAMKK2 | 36.6% | 63.4% |
| 5 | PKG2_PRKG2 | 25.7% | 74.3% |
| 6 | ITK | 24.4% | 75.6% |
| 7 | COT1_MAP3K8 | 24.1% | 75.9% |
| 8 | CDK6_CYCLIN_D3 | 23.3% | 76.7% |
| 9 | MUSK | 22.8% | 77.2% |
| 10 | GSK3A | 21.5% | 78.5% |
| 11 | AURORA_C | 20.4% | 79.6% |
| 12 | TTBK2 | 20.1% | 79.9% |
| 13 | LYN | 19.0% | 81.0% |
| 14 | PHKG2 | 18.4% | 81.6% |
| 15 | CK1D | 18.4% | 81.6% |
| 16 | STK39_STLK3 | 18.0% | 82.0% |
| 17 | PLK3 | 17.6% | 82.4% |
| 18 | P38A_MAPK14 | 17.3% | 82.7% |
| 19 | MEKK3 | 17.2% | 82.8% |
| 20 | EPHA4 | 16.5% | 83.5% |
Selectivity landscape
Where Trametinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Trametinib.
Annotations
Sign in to read and post annotations.
Loading…